ABVC
ABVC BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.96
−3.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (796.0K) | — | 509.6K | 152.4K | 969.8K |
| Cost of Revenue | — | — | 763.00 | 302.0K | 286.4K |
| Gross Profit | (796.0K) | — | 508.8K | (149.6K) | 683.4K |
| Operating Expenses | |||||
| R&D Expense | 114.8K | 121.1K | 179.3K | 1.1M | 2.7M |
| SG&A Expense | 6.1M | 7.0M | 5.0M | 5.6M | 13.1M |
| General & Admin Expense | 6.1M | 7.0M | 5.0M | 5.6M | 13.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 253.0K | — | — | — | — |
| Total Operating Expenses | 6.5M | 7.2M | 5.2M | 6.6M | 15.8M |
| Cost and Expenses | 6.5M | 7.2M | 5.2M | 6.9M | 16.1M |
| Operating Income (EBIT) | (7.3M) | (7.2M) | (4.7M) | (6.8M) | (15.1M) |
| Non-Operating | |||||
| Interest Income | 133.3K | 167.1K | 87.4K | 185.5K | 187.8K |
| Interest Expense | 155.2K | 415.9K | 825.9K | 1.3M | 294.0K |
| Net Interest Income | (21.9K) | (248.8K) | (738.5K) | (1.1M) | (106.2K) |
| Other Non-Op Income/Expense | (1.1M) | (1.2M) | (664.3K) | (1.3M) | (400.2K) |
| Non-Operating Income (excl Interest) | 929.3K | 785.7K | (161.6K) | (55.6K) | 106.2K |
| EBT (Pre-Tax Income) | (8.4M) | (8.4M) | (5.4M) | (8.0M) | (15.5M) |
| Income Tax Expense | 527.00 | 24.2K | (110.5K) | 256.0K | 797.8K |
| Bottom Line | |||||
| Net Income | (7.9M) | (7.9M) | (4.9M) | (7.8M) | (16.4M) |
| Earnings from Cont. Ops | (8.4M) | (8.4M) | (5.3M) | (8.3M) | (16.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.9M) | (7.9M) | (4.9M) | (7.8M) | (16.4M) |
| Per Share | |||||
| Basic EPS | ($0.29) | ($0.39) | ($0.42) | ($1.80) | ($5.20) |
| Diluted EPS | ($0.29) | ($0.39) | ($0.42) | ($1.80) | ($5.20) |
| Revenue Per Share | ($0.03) | $0.00 | $0.04 | $0.04 | $0.31 |
| Shares | |||||
| Basic Shares Outstanding | 26.1M | 23.3M | 11.7M | 4.3M | 3.2M |
| Diluted Shares Outstanding | 26.1M | 23.3M | 11.7M | 4.3M | 3.2M |
| Profitability Metrics | |||||
| EBITDA | (7.8M) | (7.4M) | (4.3M) | (6.3M) | (15.2M) |
| D&A | 414.5K | 504.8K | 200.9K | 380.4K | 23.8K |
| EBIT | (8.2M) | (7.9M) | (4.5M) | (6.7M) | (15.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026